NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the European committal has given orphan drug designation to Natpara® (recombinant human parathyroid internal secretion (rhPTH[I-84]) for the treatment of hypoparathyroidism. Natpara is a bioengineered replacement for endogenous parathyroid internal secretion (PTH) that NPS has developed for the treatment of hypoparathyroidism, a rare endocrine disorder in which the consistence produces insufficient levels of parathyroid internal secretion, a corpus regulatory of the consistence's mineral homeostasis. Orphan drug designation in the European Union (EU) is given to products that are designed for the diagnosis, prevention or treatment of rare diseases that are animation-forbidding or chronically debilitating. A disease is defined as rare in the EU if it affects no to a greater extent than five in 10,000 people.
"We are very pleased that Natpara has received orphan drug status in the EU," said Francois Nader, Ancient Line payoff, president and chief executive ship's officer of NPS Pharmaceuticals. "As a global rare disease biopharmaceutical company, this aligns with our commitment to deport innovative therapies that transform the lives of patients conclusion to the cosmos. Hypoparathyroidism patients face a significant burden of disease given the multitude of physical, cognitive, and emotional symptoms associated with this disorder. Natpara could substantiate the 1st PTH replacement therapy to treat this condition."
The company was also given orphan drug status by the U.S. Food and drug administration (FDA) in 2007. The company submitted its U.S. Biologic licence covering to FDA in October 2013.
SOURCE NPS Pharmaceuticals, Inc.
62ce5c92-2c1a-4ba6-bbfa-6076fd2fad4d|0|.0
Posted in: Medical condition News | Pharmaceutical News
Tags: Anxiety, gore, bone, Brain, Calcium, depression, Healthcare, internal secretion, Hypocalcemia, Hypoparathyroidism, Metabolism, Muscle, Rare Disease, Vitamin, Vitamin viosterol
No comments:
Post a Comment